Laying Out Lessons Learned from Early Development of ADCs

• Understanding why the dose of ADC matters
• Explaining how durability of response may be a better predictor of activity than ORR in early ADC trials
• How can we use predictive biomarkers to improve ADC patient selection; should we be looking beyond biomarkers of response to biomarkers of toxicity?

Speakers:

Mohit Trikha

President

Kivu BioScience, Inc.